Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Conference · 2026-11-17
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
Hi, everyone. My name is Maury Raycroft. I'm one of the biotech analysts at Jeffrey's. I'm happy to welcome the team from Ultrogenics. We've got Emil Kakas, the CEO, and Howard Horn, the Chief Financial Officer. Thanks so much for joining us today.
Happy to be here. Thanks, Maury.
And we're going to do fireside chat format, so maybe for those who are new to this story, if you can give a one-minute intro to Ultrogenics.
Sure. Ultrogenics is a company working on rare and ultra-rare disease treatments. We've been on the public markets for 12 years, and we have six approved programs in that time, including two gene therapies, monoclonal antibody, enzyme, and small molecule treatments for a variety of rare and ultra-rare diseases. We work in bone endocrine, neuro, and also in... Inborn errors and metabolism. We're a diversified global company. We have commercial operations in North America, South America, Europe, Middle East, and Japan. And we believe in exploiting the full global markets as a way to build our business. Our basic business of four original products have been growing at around 20% a year for the last few years, and we just added two new gene therapy approvals, which we can talk more about. They're launching now. And with those approvals, we also got two PRVs. We had a program, Angelman, treatment for GTX12 that did MIST recently, which led to a need for cost containment controls, which we have implemented, which put us on track to be next year a profitable company, which we expect to be a billion-plus in revenue, and to be meaningfully profitable, and to be able to operate a more narrowed-focused R&D footprint going forward. And so we're excited about this next stage of getting to profitability, which was, I think, our original plan. And we continue to work on an R&D platform, which will generate appropriate upside, but we're also being driven by our commercial franchise. And we can talk more about the launches and the other programs as we get through.
Yeah, I think that's a great intro, a lot to talk about. And maybe starting first with commercial and profitability, you've reiterated the gap profitability and positive operating cash flow in 2027. Can you walk us through the major assumptions underpinning that guidance? I'm going to talk about the base business growth, contributions from ganglycos and VUV, and the level of pipeline investment, particularly if citruzumab requires additional development.
Yeah, I think I'll just start by saying that. We always had a plan to become profitable. In this case, we need to do it at that moment in time without an engagement revenue source. But we had enough revenue to base it, and we could right-size our development organization and get us there, and to meaningful profitability. I'll let Howard put together some of the pieces of that story, since he's been intimately helping putting that together.
Sir, Maury, you're right. We've got it to full year gap profitability in 2027. We also said positive cash from operations. So that's a real turning point for the company. The assumptions to get there are that the current four programs continue to grow. As Emil mentioned, they've been growing well for many years. And then some supplementation from the two gene therapy launches to build the top line. And then we had recently given guidance on R&D and SG&A, where we talked about ceilings of 350 million next year for R&D and a ceiling of 375 million next year for SG&A. So those are the building blocks of it. Got it.
Yeah, that makes sense. And maybe starting with the expense guidance there, you're saying those are ceilings, so that implies the floor could be lower. I guess, what can you say about those ranges?
Yeah, at this point, we've just commented on the ceiling part of it, but what we really wanted to do is give people comfort that we had during the corner, and I hope that came through.
Or some of the levers that could potentially get you lower on expenses, too.
Yeah, so obviously if you choose not to do a program or you choose not to go into a region or expand something, or if you chose to reduce on spend. So it's all the normal levers.
Yeah, okay. Okay, and for Chris Vita, third quarter revenues came in at $109 million. How much of the shortfall was North American shipment timing and other technical issues versus true underlying demand? And what are you seeing in fourth quarter so far that gives you confidence in the strong rebound of about $142 to $162?
Yeah, I think, importantly, we give full-year guidance, and we, at the outset of the year, said for Crespita, $500 to $520 million, and we've reiterated that each quarter, and we did so again in our third-quarter call. So we feel good about the full-year part of it. Maybe what you're asking is, we talked about a sawtooth pattern that goes through the four quarters of the year, and that's driven by ordering patterns in some regions and seasonality and others, and we've followed that pattern. So the concept of a shortfall isn't the way I'd think of it. It's followed the saw two, three predictive.
Two and four is higher. One and three is a little bit lower. It's been that way forever. But there is always a little bit of lumpiness in Latin American ordering. You know, there may have been some that went in the Q2, less Q3. And there's another factor that our actual royalty rate does rise through the year. And so fourth quarter always is bigger for us because the royalty at the beginning of the year starts at a lower point, It actually goes up as time goes on through the year, so because of the way the royalty is designed. So we're comfortable that we're going to hit the mark.
Got it. And you mentioned the 20% growth rate, I guess. How much growth is from new patient search versus geographic expansion and persistence?
It depends on the product. You know, I think Mepsevi's been pretty stable, so that's not an issue. For DeJolvi, a lot of the growth in the U.S. is maybe a single digit, but we're adding Japan is in launch mode right now. So additional territories were sold in the Middle East and Japan have been growing that product particularly. Chris Feet has been growing in Turkey and Latin America through just new patient starts continuing. Yeah, FKISA has been growing in both Japan and in Europe. In fact, last year, FKISA kind of outperformed, and that kind of helped us. So it's addition of territories and it's organic growth, the combination that's adding. And what's been encouraging is things like the amount of Middle East work has really, we're talking about the Middle East a lot for other reasons, but We have dojovy patients in Kuwait, and Dubai, and in... Kingdom Saudi Arabia as well, as well as Turkey. So we have some more programs in Middle East doing better than we would normally think about, right? So that's been definitely a plus. Canada has done well, too, which normally we don't in rare disease, we don't think of Canada. But with the private insurance situation, we're actually getting more traction in Canada and doing well there as well. So these outlying areas are still building up revenue and adding the story, which is why from our beginning, we wanted to be a global story, because once As long as you do the risk, then you can generate revenue streams for all these different countries because everyone has kids that need to get treated and want to get treated, right? And there's that level of urgency that always drives it. So we think now we're in that point of leveraging that commercial infrastructure and building up a real global business. And then every year, different territories, additional products or territories or just organic growth will help drive our business forward. That's why if you look at our deck, you can see the steady growth of our revenue, which is It's just continuous. Organic addition of patients at additional territories and countries that we're in, as well as new products coming out. I think it's been a really solid part of our story and maybe not fully valued.
Yeah, it made sense. And with Chris Vita, maybe talk about just where peak sales could go there. So prior to 2032, loss of protection on the IP. And with Kirin, they've got a next-gen antibody. But what else is there out there in the XLH space, and how do you think about competition?
Well, Crisfita is an excellent product, and really it's like a second-generation antibody. It's fully bioavailable, subcutaneously. It has no anti-drug antibodies, no hypersensitivity. It's a really beautiful drug and with high compliance and persistence because once you get your phosphate to normal, you feel good, and if you lose that, you feel it, right? So there's an immediate short-term impact to people. Which is why that drug's done so well. It's continuing to grow everywhere. I think the U.S. is going to continue to grow. We just got the Q2W dosing in the U.S., and there's a lot of patients going on to that, which will increase revenue. We have new Boeing data from the PEDS, which I think should drive more pediatric adoption, because we think there's room even just in the U.S. to get more penetration. We've talked to our colleagues at Caren about that, and they're agreeing. So I think Cresfita continued to grow. I think it has not stopped at all, and it is continuing to grow, so we feel good about that continuing. Now, with regard to LOE, in rare disease drugs, it's never quite the same as other really large market drugs. These are all specialty pharmacy, patient drop ship, you know, and specialty pharmacy related. They're not going through the traditional wholesaler channels and prescription process, right? It's a very different thing. So they generally don't have the same LOE effect that you might see for others. That said, we're not ignoring it. Kirin has been working on molecules. We've been working on molecules. So we have new versions, but we have to meet the standard of the proc. We have, which I just told you is excellent, and now you want to make it better, maybe less frequent dosing, but maybe a little more potent to try to enhance the efficacy, and we're working on it together. And we'd expect to be able to get something launched in time to before LOE occurs, and that we could put out and move forward. So we're preparing for it. We don't, we understand it's there. I don't think it's as big a risk as some think, but we're still covering it. We'll take care of it.
Would the economics be the same or would that?
There are probably some subtle differences because we're in a different stage of the company in a different place and who's doing what is different. But we'll come up with, I think, reasonable economics that will reflect the value of both parties and the economics that are good for both. I'm sure we can do that. We've had a good partnership and we've done very well together all these years. Part of it is just because they developed a great product. But we were good at getting it developed efficiently and fast, and so that partnership, we have a share of how we get this done, and I think that can continue, and we can still share the rights and the value for global work that we're doing together.
More updates on that next year?
Yes, we presume so, yes, sometime next year. I mean, they're still doing the work in the Phase 2 next year. Somewhere between there and the year after we'll be going hardcore into what needs to be to get to approval. The idea to get approval that Eloise, the first one is 2032. And there's one that comes after that for a second patent.
2035.
The second one.
Yeah.
Yeah. So You know, our goal would be to get launched before those time frames, which we think we can do. We did the original, but I'm going to keep mine in four years. So we think we can get this part done in that time frame, too.
Got it. Okay. And so let's shift gears. We'll talk about some of your programs. There's been renewed interest in citruzumab for that one. Where exactly are you in the FDA process today, and have you had a formal type E meeting yet, or when could that happen?
Well, one thing, we've had multiple meetings with FDA, so the type B meeting is a milestone-based meeting, right? That's like a pre-BLA meeting or an end of phase two meeting, right? Those are milestone meetings. When it's not a milestone meeting, they're usually called type C meetings or type D meetings if they have a narrow focus, but who cares about the regulatory meeting? We met with them a couple times. We're working through that process. We're talking about what's required. We have said in the past FDA had wanted some additional prospective data. The question is what does that truly constitute? And we haven't settled because we're trying to figure out how to get there quickly. We expect there to be more trial data in our plan next year and budget wise it covers the potential of a study it's already built in right into our budget plan or profitability plan just to be clear. We are collecting still collecting data on patients. 80% of the patients stayed on drug, want to stay on, do not want to come off, and PIs are very dedicated to it. So there's a lot of strength behind the desire for that product. We are going to find a way to get through. What we're trying to do is find how to get it as promptly through, but I don't think I'd want the street anticipating that it's going to get filed soon, but I want them to understand there's probably some data we have to collect, but how much it is, how long it takes, that'll be some of the things we'll have to figure out, but we're dedicated to getting it done because we think cituzumab is a meaningful product for OI, and I think the PIs are supportive of that as well as the patients.
Got it. And if we look at the data, the three or greater prior faction subgroup stands out. Can you talk more about this population beyond fracture history? And does this population, is there anything beyond the fractures that biologically or clinically makes them distinct?
Well, first, let's talk about the orbit study. The orbit study was designed to have a minimum level of fractures, which was meant to be at least one, and our thought of the average would be about two if you have a threshold of one that the average, what ended up happening, the average was like 0.5. And so that's part of the way the study failed. We didn't have as much fracture as we could. Now, we built in the study a strata of greater than 3 or below 3, right? So we stratified by greater than 3. So 3 is a number we already have been talking about. So when you look at the above 3 strata, you saw a meaningful treatment effect, right? It's in the 40 to 60% range. So we see a meaningful treatment effect there. Had the whole study had that strata, the study would have been successful. But unfortunately, we had too many mild patients. So, we think that that... Severity is a very common issue in rare disease programs, where you don't quite get enough severity, you have enough signal, but we feel that the more significantly fracturing patients have a meaningful decrease is in the 40-60% range, and the same was true for the COSMIC study. That study showed an even bigger effect, again, in the higher fracture subset. So all we're saying is the patients really have enough fractures where you can measure the events. We see the treatment effect in the 40 to 60% range, which is what we were thinking we would have all along. So it tells us why it didn't work, but it tells us that it does work. The BMD effects are profound, 1Z-score improvement, P-value is very strong. What was supportive beyond fractures was that the... The pain of physical function scores, there were two endpoints in orbit, and this is a placebo-controlled trial. Both endpoints were either statistically significant or at least trend, and that showed us that there's a pain physical function effect in the orbit study. However, we missed the primary AFR endpoint that was chosen, and this was chosen historically by the way FDA looks at osteoporosis, really, because it's a very narrow kind of view. We've been discussing how to look at fractures, what about clinical benefit in general at OI, and how to interpret our data to get them to appreciate and understand the data, and that's where this has gone. And I think what we can show is that the things like the vertebral column, which where the The bone marrow density increases very quickly. You see a very profound effect on vertebral column, which is extremely important, especially in little kids. The long bones may take more time. And so depending on the bone and the time frame, this is factors in OI. But what I can say is that whether you think about pain, physical functioning, fractures in different bones, we see an effect that's pervasive across the patients. And we think then there's a drug we need to investigate with FDA. How do we get the support for this? How fast can we get it to make it accessible to patients? But we're confident we can get there. Just how fast is a question that I think everyone's wondering about.
Got it. And I guess with the data that you're collecting from the current study, including the open label extension, do you think that should be sufficient? Or do you think you're going to need another study? I guess what's the base case scenario going forward?
Well, I think the base case, people assume that there's more clinical trial data to collect. That's, I think, the base case. The crossover data... Is another piece of data that's coming that will be additional group of patients who are a control arm that went over on the drug? It's an additional piece. Will that be enough? It's not a parallel control type design, right? It's crossover data. I think that could be helpful. However, FDA's tendency is to want prospective control data and not crossover type data. In RARE, in multiple programs I've been involved with, we have used crossover data to help support efficacy case statements. But FDA is always a show-me situation. You don't get answers by asking hypothetical questions. You've got to show them the data and negotiate. So just to be clear, you don't, with FDA negotiating, The idea that you go to one meeting, everything's solved, right? It's very simplistic. When things are complex, it can take a little bit of time, and our goal is to work with the FDA closely to find a good and more rapid path. But I would not assume that right now, but I think the crossover data is another piece of data that we can bring to the table. And there were around, of the peds, there were about 30-some patients in the ORBIT study that were pediatric, Patrick, and there were... You know, then another 36 that were in the cosmic study on the bisphosphate arm, right? So those patients have crossed over and will be, are being treated now. So that gives us another bite at the apple, if you will, another group of patients that were treated, we can show and compare what they had. The patients are very happy to have crossed over, by the way, and I went to the OIF meeting and talked to a lot of families who were actually in the crossover and how important it was to them. The community gave us an award for the work we're doing with them, but I think the truth is, oh, it's just not had much, and this is something that's doing something more profound than you've ever had, so we have a responsibility to get there, both for the patients and for, of course, investors that watch us.
And so if FDA wants another prospective study, could you use the current data set for accelerated approval and then potentially do, like, a post-marketing commitment for that study? Is that possible, or...?
It's one possibility. I don't want you to create that as the base case, because I think that's a... Lower probability case, but obviously better case, but I don't want that to be the expectation at this point. I think we should expect they may need more prospective data, but I do think we should be able to try to leverage it, but I don't think you should expect that at this point.
Got it. And when is the next OLE data cut? And as far as the crossover data from there, has FDA commented on that and how meaningful that would be?
We haven't provided any crossover data yet.
It would need to be at least a year.
Well, crossover data they know doesn't have a parallel control arm, right? So their natural reaction to that is that it's not as valuable. But the FDA always says certain things, and there's a dance and a chess game that goes on in terms of understanding. That's what they say. Let's see what it looks like. We have gotten data from crossover design. The original received approval for pediatrics for patients on oral phosphate, and they crossed over onto drug. That was the approval trial. All right. But originally they said no, but then eventually we got them to say yes. Because the data were compelling. And I think a discussion with FDA with data that's compelling is always a better place to be than trying to get hypothetical agreements. So this is why you have to understand I've negotiated a lot of FDA agreements, Eric and I both, Eric's our CMO here. You have to understand how they have to operate. They need certainty. They can't make agreements to things that they don't know, they can't see in their hands. So when we get the crossover, we'll be able to look at them, talk through it. But whether that gets us to a file, I think is a question I would say. I would not assume that. I would assume that another trial is probably needed. But I would, right now, we're working it. And when we get an answer, we'll let you know.
Okay, that sounds good. And let's shift gears. We'll talk about the gene therapy launches underway. Maybe provide some perspective on how those are going and wondering how many patients have been identified, referred to a QTC, and are scheduled to treatment to date.
Yes, so first of all, our choice of gene therapies are things that are patient urgent. The thing that drives gene therapy success so far has been urgency. Is this the only way to get them treated? Phi UV for San Filippo, they're dying. Those kids are going to die. Their brains lack luck, SMA. GST1 is also urgent, maybe not as urgent as Phi UV. We're having lots of star forms, and Phi UV particularly because it's so crazy urgent. We have already treated. We have multiple patients, and so far, I think the launch is going well. We'll provide the QTCs are more than 30, and we expect to have 40 by the end of the year. Early next year, we'll private where we are in QTCs, where we are on start forms. And revenue that we'll have from this year. We'll announce then. We won't project the launch trajectory of products. We don't do that for the first six quarters. It's our habit. But so far, I think they've gone well, and we're pleased with what we're seeing. Did I miss anything? Nope, you got it. Okay.
And where are the biggest drop-offs or delays in the funnel to get patients on therapy? These are high-priced drugs. Has reimbursement or payer requirements been a bottleneck?
Well, no. We did a lot of conversations. I personally was involved in the payer conversations during the summer, and I'd go to try to raise the caliber who's on the other side until we get decision-makers on the other side. Usually, if the CEO comes, they will do that. So we had a lot of discussion with the major plans to make them understand the urgency in the situation. And I think we got their understanding. When you go to launch, though, you're always being approved under exceptions, right? And those processes that take some time, right? So that's a time thing. But right now, we haven't seen reimbursement as a block. We've had good reimbursement success. And I think the policy is going to be coming to label so far. And so we're encouraged by how it's looking. We don't think that is going to be a problem. I think it's Sites getting set up and, you know, ready to treat. You have to get antibody testing done and some certain other things. But so far, I think it's gone pretty well. And patient urgency is driving, driving the story.
Got it. And you've invested heavily in internal manufacturing. At what annual patient volume can the gene therapy products reach biologics like COGS and gross margins?
Well, we invested appropriately because the truth is gene therapy products are expensive to make. Thank you. It's far better to keep those kind of complex products under your own control. We contract manufacture. Most of all the other products, right? But in this case, very high cost, complex products, you're better off in your control from a margin standpoint and just a cost control and flexibility standpoint. It's just always been the case. So we did it where we needed to do it, but we are very thoughtful on business decisions on manufacturing. We don't just do it just to have it control. It has to make business sense. The plant we built, we think we can leverage. It's appropriately sized to leverage, and we're able to make the drug subs and drug product for the genglycose product. The drug for Faiubi, it's made, the drug subs is actually made at our partner, and we do the drug fill finish. The capacity there is sufficient capacity to what we need. If demand continues and grows, it's possible we will need to increase the amount of our partner drug substance production to keep up. But so far, I think we've been pretty well sized, and I think we'll be in good control. Did I miss anything on the financial aspects of that? But I think one thing is very important to understand our burn, because people talk about our cash burn in the last couple of years, but the last couple of years, we've been developing launch material for four products, right? Two of those are approved. So we've expensed a lot of product that we've put. On our product balance sheet, if you will, not on the cash balance sheet, but that product is now what's going to be sold now through next year. It's all expense product. So a lot of the spend that happened in the last couple of years are actually product that we will be able to use. And I think that's important that people understand that there's some hidden value that's coming back to us now.
Makes sense. And on the BD front and just kind of replenishing the pipeline, any more perspective on that that you want to share?
We have... been a really good engine for innovation. We have a couple of programs that are already taken through IND enabling that we mentioned, but we're going to be very smart about operating the footprint. As long as everything goes well, we have the potential to have two more INDs already ready to go. One is for preteen transfer deficiency, the other for CDKL5 deficiency. Both are 30,000 to 50,000 kind of population size that we think of as potential billion-dollar rare disease programs and totally unmet needs, We're going to be smart about choices, and we're not going to build out a whole bunch of new product, and we're going to stick to our profitability goals, and if we do need deals, we have to be very smart, value-creating deals.
Got it. Maybe just closing out, we're out of time, if you want to comment on cash position and key capital side.
Yeah, we concluded the quarter with $401 million, and then we were able to add to that another $350 net from our two PRV sales. So as Emil mentioned, that's a good, strong balance sheet, and we plan to add to it.
It's a grand 700 million. We've got plenty of cash, and we'll be adding cash next year. So I think we're in a great place from all around running the business. And I'm happy to be a product company that's going to be driven by six products, profitable, global, rare disease company, and done that in 12 years. I think that's a real win. And we do have to deliver some catalyst upsides. I appreciate that, and we're going to work toward getting that as well.
Amel, Howard, thanks so much for joining us today.
0:00 to 26:41 · One card per analyst, follow-ups included. Each plays from its start, and the one being answered is marked.
Hi, everyone. My name is Maury Raycroft. I'm one of the biotech analysts at Jeffrey's. I'm happy to welcome the team from Ultrogenics. We've got Emil Kakas, the CEO, and Howard Horn, the Chief Financial Officer. Thanks so much for joining us today.
Emil Kakkis: Happy to be here. Thanks, Maury.
Also speaking: Howard Horn